Michelle Horn
Country Medical Director for GSK Canada
From R&D to collaborations that help translate scientific breakthroughs into tangible outcomes, GSK Canada is contributing to a stronger health care system.
Canada’s health care system is facing growing pressures, from an aging population and rising rates of chronic disease to rapid technological change. At the same time, advances in life sciences are creating new opportunities to improve patient outcomes and strengthen health care systems.
Mediaplanet spoke with Michelle Horn, Country Medical Director for GSK in Canada, about the opportunities, challenges, and innovations shaping the future of health care in Canada.
Mediaplanet: The world is changing rapidly, and with it, the landscape of health care. From global health events to technological leaps, there’s a palpable sense of urgency. As Country Medical Director for GSK in Canada, you’re at the forefront of life science innovation. In this dynamic environment, what does “life science innovation” mean to you and GSK Canada specifically, and why is this moment so critical for advancing it?
Michelle Horn: That’s an excellent question that gets to the heart of what we do. For GSK, life science innovation is fundamentally about getting ahead of disease together. It’s about bringing forward transformative medicines and vaccines that truly make a difference in patients’ lives. But the “why now” is crucial. We’re living through a period where the convergence of factors — an aging population, the rising burden of chronic diseases, and the accelerated pace of technological advancement, particularly in AI and personalized medicine — makes innovation more urgent and impactful than ever before. We see this as a pivotal moment for Canada to strengthen its position in life sciences, ensuring Canadians benefit from these breakthroughs. It’s not just about discovery; it’s about the entire journey from scientific breakthrough to ensuring equitable access and real-world impact for Canadians in this rapidly evolving context.
MP: Canada has a robust life sciences ecosystem, from excellent university research to smaller biotech startups all the way to multinational pharmaceutical firms, yet also faces unique challenges in health care delivery. Where do you see GSK Canada playing a unique leadership role within this environment, particularly given the external changes and pressures you mention?
MH: Our leadership is demonstrated through several key areas that directly address Canada’s current needs. Firstly, our deep R&D pipeline is truly differentiated, focusing on areas of high unmet medical need —respiratory and immunology, oncology, and infectious diseases. For instance, our pioneering work in exploring novel treatments for chronic hepatitis B isn’t just about a new drug; it speaks to the broader challenge of chronic disease management and the potential to reduce long-term health care burdens, which is increasingly vital as our population ages.
These innovative approaches aim to fundamentally change the course of diseases. They could potentially lead to functional cures that free patients from lifelong treatment and significantly reduce the risk of severe complications, improving the overall health of our population and creating a stronger, more resilient Canadian economy.
Secondly, we place a strong emphasis on collaboration and partnership. We understand that no single entity can tackle complex health challenges alone. The pandemic, for instance, placed a spotlight on the critical need for integrated health strategies.
GSK Canada actively partners with academic institutions, research networks, patient advocacy groups, and government bodies. These collaborations are essential — they help translate scientific discoveries into tangible health outcomes, for example, through clinical trials that bring cutting-edge therapies to Canadian patients sooner.
We’re proud to contribute to Canada’s clinical research capacity, providing opportunities for Canadian researchers and patients to participate in global studies and strengthening our collective health security.
MP: You mentioned Canada’s unique health care landscape. How does GSK ensure its innovative solutions are relevant and accessible across such a diverse country, especially when addressing broad health trends like chronic disease?
MH: That’s a critical point, and it ties directly into the challenges and opportunities of the moment. Canada’s vast geography and diverse communities, coupled with increasing rates of chronic conditions like diabetes and cardiovascular disease, require a tailored approach. We engage extensively with provincial and territorial governments, health care providers, and patient groups to understand specific regional needs and ensure our innovations are integrated effectively into local health care pathways. This includes working to overcome barriers to access, whether they’re geographic, economic, or related to health literacy.
Our goal is to ensure that when a new medicine or vaccine is approved, it reaches the Canadians who need it most in a timely manner, regardless of where they live. We also focus on generating real-world evidence in the Canadian context. This data helps us demonstrate the value of our innovations within Canada’s health care system, supporting informed decision-making by policymakers and health care professionals who are grappling with how best to allocate resources to meet growing health demands.
MP: Looking ahead, what are the biggest opportunities and challenges for life science innovation in Canada, and how is GSK Canada preparing for them, particularly with the pace of technological change and global economic shifts?
MH: The opportunities are immense, especially with the rapid convergence of AI and personalized medicine, which promises to revolutionize how we prevent and treat disease. GSK is embracing these technologies globally, and we’re keen to leverage them within Canada to enhance our R&D efforts and improve patient care.
However, challenges remain. To be successful, a predictable and efficient regulatory environment is required — one that keeps pace with scientific advancements to ensure timely access to new therapies. Furthermore, global economic shifts highlight the importance of a robust domestic life sciences sector. From GSK Canada’s perspective, we’re actively engaging in policy discussions to advocate for frameworks that value and support innovation. This includes competitive pricing frameworks and measures that encourage private sector investment, all designed to ultimately benefit Canadian patients and the Canadian economy.
These conversations are accelerating as Canada and the United States review their important trade relationship under the Canada-United States-Mexico Agreement. We believe a strong life sciences sector is vital for Canada’s economic prosperity and its health security, especially in a competitive global landscape. Our ongoing investment in Canadian talent and research infrastructure, dating back to 1903, underscores our long-term commitment to this country.
MP: Finally, what message would you like to convey to government and decision-makers regarding GSK Canada’s role in the future of Canadian health care, particularly in navigating these current dynamics?
MH: My message is clear: GSK Canada is a committed partner in building a healthier, more resilient Canada. We’re not just a pharmaceutical company; we’re a science-led organization dedicated to getting ahead of disease.
Our innovations, collaborations, and deep understanding of the Canadian context position us as a leader in life sciences. We’re here to work hand in hand with government and stakeholders to ensure that Canadians continue to benefit from world-class medical advancements, improving health outcomes and contributing to a thriving society.
As health challenges become increasingly complex and interconnected, and technological progress unlocks new possibilities, the need for collaboration has never been greater — and together, we can make a meaningful difference in the lives of Canadians.
To learn more about how GSK Canada is advancing health care, visit www.gsk.ca.